

1626
Rhw

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/313,524	
	Filing Date	May 17, 1999	
	First Named Inventor	Reichenbach, et al.	
	Art Unit	1626	
	Examiner Name	Solola	
Total Number of Pages in This Submission	3	Attorney Docket Number	5043-103 US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Bruce M. Collins
Signature	
Date	November 8, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Typed or printed name	Mickey Cherry		
Signature		Date	November 8, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



LD9003 NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit: 1626
Examiner: Robert Gerstl
Applicant: Reichenbach *et al.*
Serial No.: 09/313,524
Filed: May 17, 1999
For: EPOTHILONES C, D, E AND F, PREPARATION AND
COMPOSITION

REVOCATION AND POWER OF ATTORNEY

Sir:

As assignee of the entire interest of the above-identified application, all former Powers of Attorney are hereby revoked and the following attorneys and agents are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected herewith:

(a) Suzanne E. Babajko, Registration No. 32,880; Deanna L. Baxam, Registration No. 45,266; Jing S. Belfield, Registration No. 45,914; Terence J. Bogie, Registration No. 44,544; Stephen C. D'Amico, Registration No. 46,652; Steven B. Davis, Registration No. 26,693; Laurelee A. Duncan, Registration No. 44,096; Sammy G. Duncan, Jr., Registration No. 46,675; Maureen S. Gibbons, Registration No. 44,121; Paul D. Golian, Registration No. 42,591; Christopher A. Klein, Registration No. 34,363; Elliot Korsen, Registration No. 32,705; John A. Lamerdin, Registration No. 44,858; Keith R. Lange, Registration No. 44,201; Maureen P. O'Brien, Registration No. 42,043; Kenneth W. Peist, Registration No. 45,006; Johnathan N. Provoost, Registration No. 44,292; Burton Rodney, Registration No. 22,076; Audrey F. Sher, Registration No. 39,024; and Mary K. VanAtten, Registration No. 39,408; whose address is Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000; and

(b) Bruce M. Collins, Registration No. 20,066; Diane Dunn McKay, Registration No. 34,586; Phillip B. Abramowitz, Registration No. 47,375; David P. Krivoshik, Registration No. 39,258; Kristine Butler-Holston, Registration No. 42,376; Patrick H. Higgins, Registration No. 39,709; Gregory C. Houghton, Registration No. 47,666; whose address is MATHEWS, COLLINS,

SHEPHERD & MCKAY, 100 Thanet Circle, Suite 306, Princeton, New Jersey
08540.

Please address all communications to Bruce M. Collins, MATHEWS, COLLINS,
SHEPHERD & MCKAY, 100 Thanet Circle, Suite 306, Princeton, New Jersey 08540.

Gesellschaft fuer Biotechnologishce Forschung mbH (GBF), a German
corporation, hereby certifies that it is the assignee of the entire title, right and interest of
the above-identified application, by virtue of an assignment from the inventors, Gerhard
Hoefle and Michael Kiffe, which was recorded in the US Patent and Trademark Office at
Reel 010171, Frame 0212, in application Serial No. 09/313,524, filed May 17, 1999,
which the present application is a division.

The undersigned is entitled to act on behalf of the assignee.

The undersigned declares further that all statements made herein of his own
knowledge are true and that all statement made on information and belief are believed to
be true; and further, that these statements were made with the knowledge that willful
false statements and the like are punishable by fine or imprisonment, or both, under
Section 1001 of Title 18 of the US Code, and that such willful false statements may
jeopardize the validity of the application or any patent issuing therefrom.

Respectfully Submitted,

GESELLSCHAFT FUEER BIOTECHNOLOGISHCE
FORSCHUNG MBH (GBF)

By:

Name:
Title:

Prof. Dr. R. Balling
Scientific Director

Dr. jur. G. Frischmann
Administrative Director

Dated:

January 13, 2004

BEST AVAILABLE COPY